[Addressing the Risk of 12 Million People by 2050] Imagina Launches 'Kenchonavi®' to Expose Risks for Over 30 Diseases, Including MCI; Shedding Light on Preventive Healthcare for a Super-Aging Society

Imagina (Headquarters: Chiyoda-ku, Tokyo; CEO: Yoshiki Sekino), a specialist group in inner branding, announced on June 11, 2026, the full-scale launch of 'Kenchonavi®'. This next-generation intestinal flora analysis service enables users to easily visualize risks for over 30 diseases at home, such as colon cancer, depression, and MCI (Mild Cognitive Impairment), a precursor to dementia. Addressing the growing concern over dementia and preventive healthcare in Japan, a dedicated 24-hour application portal (https://kenchonavi-lp.netlify.app/) was also opened to the public.

This service employs 'Covariance Structure Analysis (SEM)', a world-first patented technology developed by Synbiosis Solutions (Headquarters: Bunkyo-ku, Tokyo), and utilizes a database of approximately 27,000 Japanese individuals to provide high-precision analysis that accounts for gender differences. Moving beyond simple 'status checks', the service aims to popularize a new healthcare habit: detecting risks at the pre-disease stage and protecting physical and brain health ('brain capital') through optimal dietary choices based on individual gut health.

Development Background: The Arrival of the '12 Million Dementia/MCI Era' by 2050. What Preventive Measures Should We Take?

As Japan becomes a super-aging society, its medical and social security systems are facing unprecedented changes. Estimates based on recent Ministry of Health, Labour and Welfare prevalence surveys suggest that by 2050, 12.178 million people—27.8% of the population aged 65 and over—will reach the stage of dementia or MCI. By 2060, the socio-economic cost of dementia (total of medical, nursing, and informal care costs) is projected to reach an astronomical 24.26 trillion yen, posing a serious challenge to the nation's economic foundation.

Furthermore, an increasing number of business professionals and modern individuals suffer from 'unexplained physical and mental malaise' due to lifestyle disruption, chronic stress, and lack of sleep. Recent medical and neuroscience research is rapidly uncovering the mechanism of the 'brain-gut axis', where the gut and brain interact. It is widely recognized that intestinal flora imbalances are closely linked not only to physical diseases like colon cancer and diabetes but also to mental and brain function disorders like depression and cognitive decline.

Given this, there is a strong demand for a 'personal self-care' system that allows for easy risk detection and promotes behavioral change in daily life, rather than relying on traditional 'symptomatic treatment' after a disease occurs.

Three Innovations of 'Kenchonavi®': Why Can We Understand Systemic Risks from the Gut?

'Kenchonavi®' is a next-generation intestinal flora analysis service supported by academic evidence and an unprecedented amount of data.

Japan’s Only Service to Determine 'MCI (Mild Cognitive Impairment) Risk' Among intestinal flora tests available to the public, this is the only one in Japan capable of identifying and grading the risk of MCI, the early stage of dementia. It serves as a powerful navigator for protecting the 'brain capital' of executives, experienced employees, and family members at the pre-disease stage.

High-Precision Analysis via World-First Patented 'Covariance Structure Analysis (SEM)' Unlike traditional tests that merely check for the presence of single bacteria, this service adopts a patented analytical method (SEM) developed by Synbiosis Solutions. By comparing results against a database of 27,000 Japanese people, it achieves industry-leading high-precision risk prediction.

Analysis Algorithm Thoroughly Accounting for Gender Differences There are distinct gender differences in the composition of intestinal flora and disease onset processes. This service provides a scientific analysis and constructs gender-specific judgment programs, comprehensively visualizing risks for 31 diseases in men and 34 in women (e.g., colon cancer, diabetes, cerebral infarction, depression, breast cancer, prostate cancer).

Painless At-Home Process and Support Program

'Kenchonavi®' eliminates the burden of visiting medical institutions and the psychological resistance to painful tests.

Simple 3-Step Process: Collect a stool sample at home using the kit and mail it. After answering a simple web questionnaire, a detailed web report will be issued in about a month.